# EDGAR Filing Document

**Accession Number:** 0001610820
**File Stem:** 0000000000-23-002624
**Filing Date:** 2023-3
**Character Count:** 2907
**Document Hash:** 7a2ba8edbd1f57554f438cfcbe0a87ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002624.hdr.sgml**: 20230413

**ACCESSION NUMBER**: 0000000000-23-002624

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230316

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BriaCell Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001610820
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1
- **BUSINESS PHONE:** (604) 921-1810

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ansell Capital Corp.
- **DATE OF NAME CHANGE:** 20140613
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-029742

## Text-Extract

```

United States securities and exchange commission logo

                       March 16, 2023

       Gadi Levin
       Chief Financial Officer
       BriaCell Therapeutics Corp.
       Suite 300 - 235 15th Street
       West Vancouver, BC V7T2X1

                                                        Re: BriaCell
Therapeutics Corp.
                                                            Form 10-K for the
Fiscal Year Ended July 31, 2022
                                                            Filed October 28,
2022
                                                            File No. 001-40101

       Dear Gadi Levin:

              We have completed our review of your filing. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                       Sincerely,

                       Division of Corporation Finance

                       Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 16, 2023

Gadi Levin
Chief Financial Officer
BriaCell Therapeutics Corp.
Suite 300 - 235 15th Street
West Vancouver, BC V7T2X1

**Re: BriaCell Therapeutics Corp.**
**Form 10-K for the Fiscal Year Ended July 31, 2022**
**Filed October 28, 2022**
**File No. 001-40101**

Dear Gadi Levin:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences